Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships, clinical studies/applications of anti-prostate cancer agents. This book provides insight on how the design and discovery process of anti-prostate cancer agents have evolved from androgen deprivation therapy to current androgen receptor antagonists/degraders. So far, no book focusing on the topic has been published.…mehr
Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships, clinical studies/applications of anti-prostate cancer agents. This book provides insight on how the design and discovery process of anti-prostate cancer agents have evolved from androgen deprivation therapy to current androgen receptor antagonists/degraders. So far, no book focusing on the topic has been published.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Dr Qiao-Hong Chen received her PhD degree in Medicinal Chemistry from Sichuan University, China. Appointed as a Lecturer in 2001, She was promoted to the position of Full Professor in 2003 at Sichuan University. She was a Postdoctoral Fellow for three years at the University of Alberta in Canada and a Senior Research Fellow for six years at Virginia Tech. She joined Fresno State in 2012. Her research interests focus on natural products-based anticancer agents. She has published 152 peer-reviewed scientific publications, as well as 5 book chapters.
Inhaltsangabe
1. Introduction: Overview of Prostate Cancer 2. Why has one got prostate cancer? 3. Androgen Deprivation Therapy 4. Anti-prostate cancer agents interacting with topoisomerase 5. Microtubule-Stabilizing Compounds as Anti-Prostate Cancer Agents 6. Androgen/Androgen Receptor Signaling Pathway and Prostate Cancer 7. Anti-Prostate Cancer Agents Suppressing Androgen Biosynthesis 8. First Generation Nonsteroidal Androgen Receptor Antagonists 9. Second Generation Nonsteroidal Androgen Receptor Antagonists 10. Anti-Prostate Cancer Agents Interacting with N-Terminal Domain of Androgen Receptor 11. Androgen Receptor Degraders as Anti-Prostate Cancer Agents 12. Radiotherapeutics for treatment of Prostate Cancer 13. Immunotherapy for Prostate Cancer 14. Radiosensitizer for prostate cancer 15. Anti-Prostate Cancer Agents Targeting Prostate-Specific Membrane Antigen 16. Anti-Prostate Cancer Agents Targeting Poly(ADP-Ribose)Polymerase 17. Combined Anti-Prostate Cancer Agents 18. Future Directions
1. Introduction: Overview of Prostate Cancer 2. Why has one got prostate cancer? 3. Androgen Deprivation Therapy 4. Anti-prostate cancer agents interacting with topoisomerase 5. Microtubule-Stabilizing Compounds as Anti-Prostate Cancer Agents 6. Androgen/Androgen Receptor Signaling Pathway and Prostate Cancer 7. Anti-Prostate Cancer Agents Suppressing Androgen Biosynthesis 8. First Generation Nonsteroidal Androgen Receptor Antagonists 9. Second Generation Nonsteroidal Androgen Receptor Antagonists 10. Anti-Prostate Cancer Agents Interacting with N-Terminal Domain of Androgen Receptor 11. Androgen Receptor Degraders as Anti-Prostate Cancer Agents 12. Radiotherapeutics for treatment of Prostate Cancer 13. Immunotherapy for Prostate Cancer 14. Radiosensitizer for prostate cancer 15. Anti-Prostate Cancer Agents Targeting Prostate-Specific Membrane Antigen 16. Anti-Prostate Cancer Agents Targeting Poly(ADP-Ribose)Polymerase 17. Combined Anti-Prostate Cancer Agents 18. Future Directions
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497